17A-甲基雄甾烷-17B-ol-3-one--dea*附表二(CAS 521-11-9):分子式 C20H32O2、分子量 304.5。
| CAS号 | 521-11-9 |
|---|---|
| 分子式 | C20H32O2 |
| 分子量 | 304.5 |
| LogP | 3.8 |
17A-甲基雄甾烷-17B-ol-3-one--dea*附表二 是一种化工化合物,登记 CAS 号为 521-11-9,分子式 C20H32O2(分子量 304.5)。
登记 CAS 号:521-11-9
其分子式 C20H32O2 由 20 个碳、32 个氢、2 个氧 组成。
别名/同义词:17A-甲基雄甾烷-17B-ol-3-one--dea*附表二 · 17A-methylandrostan-17B-ol-3-one--dea*schedule ii
17A-甲基雄甾烷-17B-ol-3-one--dea*附表二 的 CAS 登记号为 521-11-9。
分子式 C20H32O2,分子量 304.5。
别名/同义词:17A-甲基雄甾烷-17B-ol-3-one--dea*附表二、17A-methylandrostan-17B-ol-3-one--dea*schedule ii。
17A-甲基雄甾烷-17B-ol-3-one--dea*附表二(CAS 521-11-9)的独立参考数据,整理自公开化学数据库。
| CAS Registry Number | 521-11-9 |
|---|---|
| PubChem CID | 10633 |
| Molecular formula | C20H32O2 |
| IUPAC name | (5S,8R,9S,10S,13S,14S,17S)-17-hydroxy-10,13,17-trimethyl-2,4,5,6,7,8,9,11,12,14,15,16-dodecahydro-1H-cyclopenta[a]phenanthren-3-one |
| UNII (FDA) | S712YZ168E |
| Molecular Weight | 304.5 |
|---|---|
| XLogP3 | 3.8 |
| Hydrogen Bond Donor Count | 1 |
| Hydrogen Bond Acceptor Count | 2 |
| Rotatable Bond Count | 0 |
| Exact Mass | 304.240230259 |
| Monoisotopic Mass | 304.240230259 |
| Topological Polar Surface Area | 37.3 |
| Heavy Atom Count | 22 |
mestanolone; 521-11-9; Assimil; Methybol; Tantarone; Mesanolon; Mestanolona; Mestanolonum; DTXSID0048973; NSC-18219; 17alpha-methylandrostan-3-on-17beta-ol; S712YZ168E; 17beta-Hydroxy-17alpha-methyl-3-androstanone; 17beta-Hydroxy-17-methyl-androstan-3-one; DTXCID3028899; 17alpha-Methylandrostan-17beta-ol-3-one
| GHS notification summary | 1.4% (1 / 69) |
|---|
| GHS notification summary | 1.4% (1 / 69) |
|---|---|
| Reported hazard statements | H312 (24.6%), H332 (24.6%), H351 (98.6%), H360 (39.1%), H362 (14.5%) |
This chemical does not meet GHS hazard criteria for 1.4% (1 of 69) of reports.
H312 (24.6%): Harmful in contact with skin [Warning Acute toxicity, dermal]
17A-methylandrostan-17B-ol-3-one--dea*schedule ii · CAS 521-11-9 · C20H32O2. UNII S712YZ168E.
数据来源:PubChem / Wikidata;与随货 COA 不一致时以 COA 为准。
English page: 17A-methylandrostan-17B-ol-3-one--dea*schedule ii